MIM
SKYE icon

MetLife Investment Management’s Skye Bioscience SKYE Stock Holding History

MetLife Investment Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,796
Closed -$38.4K – 2901
2024
Q2 		$38.4K Buy
+4,796
New +$56.9K ﹤0.01% 2802

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

MetLife Investment Management's SKYE Position: Q3 2024 in Review

MetLife Investment Management sold out of Skye Bioscience (SKYE) in Q3 2024, closing a stake of 4,796 shares — an estimated $38.4K sold.

MetLife Investment Management first reported a position in SKYE in Q2 2024 and held it in 1 quarter. The position peaked at $38.4K in Q2 2024. 74 funds tracked by Wall St. Rank hold SKYE as of Q3 2024.

  • MetLife Investment Management reported no remaining Skye Bioscience position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 4,796 Skye Bioscience shares in Q3 2024, an estimated $38.4K.
  • MetLife Investment Management first reported a position in Skye Bioscience in Q2 2024 and held it in 1 quarter.
  • MetLife Investment Management's Skye Bioscience position peaked at $38.4K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.